Therapeutic Drug Monitoring Market

Global Therapeutic Drug Monitoring Market Size (2024 to 2029)

The global therapeutic drug monitoring market is forecasted to grow at a CAGR of 7.33% from 2024 to 2029 and will be worth USD 2.84 billion by 2029 from USD 1.99 billion in 2024.

Therapeutic drug monitoring is a medical procedure for detecting the concentration of a specific drug in a patient's bloodstream at various time intervals. It's used to keep a steady volume of medication in the bloodstream without causing side effects. Therapeutic drug monitoring is employed in just a few medications and only those with a restricted therapeutic window. It's also employed in medications that have a lot of pharmacokinetic variation. Therapeutic drug monitoring begins with the start of treatment. It includes determining a prior dosage regimen appropriate for the patient's age, BMI, weight, organ function, and other clinical factors.

MARKET DRIVERS

The growth in the adoption and preference of personalized medicine is expected to boost the global therapeutic drug monitoring market.

The demand for personalized medicine is rapidly growing worldwide due to the increased need for improved treatment outcomes with fewer adverse effects from the medication. Advanced treatment techniques such as pharmacogenomics, gene testing, and proteomics are also projected to drive market expansion. One of the primary factors fuelling the growth of the global TDM market is the rise in antimicrobial resistance. The global therapeutic drug monitoring (TDM) market is also growing due to the number of people requiring round-the-clock care, the number of patients admitted to healthcare institutions, and a significant increase in testing volumes. One of the other key drivers for the worldwide therapeutic drug monitoring (TDM) market is the rising need for organ transplant surgeries. The importance of TDM equipment in organ transplant procedures is attributed to this trend.

This powerful tool for dose individualization is beneficial in measuring drug concentrations in plasma. It utilizes the principle of studying the effect of a particular drug during its concentration in the blood since it is easier to correlate the relationship of the therapeutic effects of a drug in this way than with the dose administered. The information then obtained helps make dose adjustments. Thus, this factor is expected to help the market grow profitably over the forecast period. Furthermore, TDM helps pinpoint the cause of failed therapy outcomes because it allows doctors to distinguish between the following confounding outcomes, ineffective drug treatments, patient medication non-compliance, and adverse drug reactions that may be confused with the effects of the underlying condition. Therapeutic drug monitoring has been observed to help manage patient duties, individualize drug therapy, improve the drug's clinical effects, and improve drug efficacy. This helps reduce drug toxicity and designs a patient-specific dosing regimen that best suits the patient for getting rid of the disease. Thus, Therapeutic medication monitoring finds its application in diagnostic purposes, which further helps the therapeutic drug monitoring market grow profitably over the forecast period. The increased need to administer individualized dosage patterns is predicted to propel the TDM market forward during the forecast period. Pharmacokinetic value, or PK, is the primary factor responsible for maintaining the complexity of therapeutic drug monitoring. Some drugs might have a significant coefficient of pharmacokinetic variation, which makes them exhibit more significant intra-patient variation between dose and effect. This could be harmful to the patient when not monitored correctly. Thus, therapeutic drug monitoring becomes very useful in such situations. Also, therapeutic drug monitoring varies depending on the intended purpose, such as estimating individual patient PK parameters. This helps set up a personalized dosing regimen to achieve the desired concentration-time profile. Thus, these factors help in the profitable growth of the global therapeutic drug monitoring market.

MARKET RESTRAINTS

High costs associated with TDM are primarily hindering global market growth.

Only major hospitals and reference laboratories with huge capital budgets are able to purchase high-volume clinical chemistry analyzers. As a result, TDM's broad use could be improved by reimbursement issues, as the costs involved with TDM are frequently substantial. In addition, poor infrastructure and skilled people are restricting market expansion in emerging economies. One of the other primary challenges in the global therapeutic drug monitoring market is the high cost of obtaining therapeutic drug monitoring treatment, which is expected to limit market growth. Furthermore, a rigorous legal environment and a scarcity of qualified resources are significant challenges to global market expansion.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Therapeutic Drug Monitoring Market Analysis By Product

The consumables segment held the most significant share in the global therapeutic drug monitoring market in 2023 and is predicted to grow at a healthy CAGR. The growing need for innovative technology-based, cost-effective kits and the widespread usage of these reagents in R&D are some of the causes driving the industry's lucrative expansion.

The equipment segment is anticipated to hold a significant market share owing to the rising diseases, which can even lead to some tissue destruction.

Global Therapeutic Drug Monitoring Market Analysis By Technology

Due to the availability of highly specific fluorescence immunoassays, the rising acceptance rate of new techniques, and the requirement of little training to operate the equipment, the fluorescence immunoassay segment led the market in 2023. The fluorescence polarization immunoassay is used to provide an accurate and reliable procedure through the established specificity of an immunoassay. In addition, it helps provide a homogeneous method with the speed and convenience of solving the problems often associated with chromatography, enzymes, and radioactivity.

Radioimmunoassay is also anticipated to hold a significant market share over the forecast period. This is due to its broad adoption in the therapeutic range of drug monitoring, such as aminoglycoside antibiotics and vancomycin in plasma. Also, it helps in quickly adjusting to the dosage of the antibiotic for the desired therapeutic result. Furthermore, the concentrations are kept below the minimum threshold to avoid experiencing adverse effects if they remain within the range.

Global Therapeutic Drug Monitoring Market Analysis By Drug Class

Over the forecast period, the antiepileptic medications segment is expected to lead the global therapeutic drug monitoring market during the forecast period. This dominance is due to increased epilepsy prevalence in recent years, which has resulted in a worldwide health burden due to the negative consequences of high blood concentrations, mandating the TDM of these drugs. It keeps antiepileptic drug concentrations nearly identical by measuring through plasma or serum.

Bronchodilators are foreseen to hold a significant market share owing to their wide adoption by asthma patients, whose number is rising. This type of medicine helps the person to breathe easily by relaxing the muscles of the lungs and widening the bronchi. In addition, they treat long-term conditions such as asthma, where the airways can become narrow and inflamed.

Global Therapeutic Drug Monitoring Market Analysis By End-User

Due to the large number of hospitalized patients with cardiac, cancer, neurological illnesses, and HIV, hospitals cover most of the market share. Furthermore, the hospital segment is predicted to grow throughout the forecast period due to rapid patient demand for hospital-attached laboratories due to increased awareness and low equipment costs.

REGIONAL ANALYSIS

Geographically, the North American therapeutic drug monitoring market controls a significant portion of the global market and is anticipated to remain the same throughout the forecast period. The dominance is due to an increase in the worldwide prevalence of various autoimmune disorders and a sharp increase in the use of the TDM for assessing the dosage regimen in the development of treatment for various cardiac indications as a result of the recent increase in cardiac deaths. In addition, individuals suffering from cardiovascular diseases in the United States have a higher demand for TDM, propelling the region's market.

The Asia Pacific therapeutic drug monitoring market is expected to grow at a CAGR of 9.27% during the forecast period, owing to unmet needs and the government's ongoing efforts to provide low-cost services to promote individualized dosage patterns for organ transplantation cases and support personalized medicine initiatives.

The Europe therapeutic drug monitoring market is forecasted to be worth USD 720 million by 2029. Countries such as Germany and UK are playing a dominating role in the Europe TDM market.

KEY PLAYERS IN THE GLOBAL THERAPEUTIC DRUG MONITORING MARKET

Abbott Laboratories, Inc., Agilent Technologies, Inc., Alere, Inc., apDia Group, ARK Diagnostics, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, and Grifols, S.A. are a few of the noteworthy companies in the global therapeutic drug monitoring market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET

• In Nov 2022, Tzield injection got approval from the United States Food and Drug Administration to treat type 1 diabetes mellitus stage 3 in adults by delaying their onset. It is also applicable for stage 2 type 1 diabetes in pediatric patients at eight years of age.
• In Dec 2022, Jazz Pharmaceuticals plc showed a high proportion of caregivers of adults and pediatric patients among all age groups with Lennox-Epidiolex oral solution prescribed for Gastaut syndrome and Dravet syndrome through the real-world data from the BECOME in epileptic and non-epileptic findings.
• In Dec 2022, Bexagliflozin tablets, the first new oral animal drug, were approved by FDA officials. It is shown to improve glycemic control in healthy cats with diabetes mellitus.
• Implementing a personalized therapeutic drug monitoring (TDM) strategy at the time of infliximab beginning does not increase remission rates in patients with various inflammatory diseases, according to study data presented at the EULAR 2020 E-Congress in June 2020.
• Hoffmann-La Roche and Blueprint Medicines collaborated in July 2020 to deliver a new treatment to people with RET-altered malignancies.
• Abbott introduced a new test in April 2020 that can detect if you've ever had the coronavirus, and it wants to produce millions of them.

DETAILED SEGMENTATION OF THE GLOBAL THERAPEUTIC DRUG MONITORING MARKET INCLUDED IN THIS REPORT

This research report on the global therapeutic drug monitoring market has been segmented and sub-segmented based on product, technology, drug class, end-user, and region.

By Product

• Consumable
• Equipment

By Technology

• Fluorescence Immunoassay
• Radioimmunoassay
• GCMS

By Drug class

• Antiepileptics
• Antibiotics
• Psychoactive Drugs
• Antiarrhythmic Drugs
• Bronchodilators
• Immunosuppressants
• Others

By End-User

• Hospitals
• Commercial/Private Laboratories
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa